文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限性前列腺癌中的微推量放疗:一项全州质量联盟分析

Microboost in Localized Prostate Cancer: Analysis of a Statewide Quality Consortium.
PubMed 文献 · Adv Radiat Oncol · 2024-10-01

该研究基于密歇根放射肿瘤质量联盟26个中心的前瞻性数据,纳入2020年10月26日至2023年6月26日接受根治性放疗的中危及高危前列腺腺癌患者。多数患者接受单纯外照射放疗(EBRT)未联合近距离治疗(71%,n=524/741),其中仅10%(n=53/524)在27%(n=7/26)的中心接受了EBRT微推量,研究期间使用率无变化(P=.62)。

要点

  • 中高危前列腺癌根治性放疗中,EBRT微推量使用率仅10%(53/524),分布于27%(7/26)的中心。
  • Grade分组4/5、MRI计划及基准标记/直肠间隔物放置与微推量使用相关。
  • 中心间微推量使用率差异显著(最低0%,最高71%,未校正P<.0001)。

核心结论

  • 尽管前瞻性数据表明EBRT微推量有获益,但在全州质量联盟中仅10%的病例在27%的中心使用,且中心间异质性显著。
  • 需要共同努力理解当前微推量使用的障碍,并期待PIVOTALboost(ISRCTN80146950)等试验的结果。

研究设计与样本

  • 利用密歇根放射肿瘤质量联盟前瞻性收集的多中心数据,纳入26个中心中危和高危前列腺腺癌接受根治性放疗的男性患者。
  • 纳入时间为2020年10月26日至2023年6月26日,前瞻性收集人口学、肿瘤和治疗相关数据及DICOM文件。
  • 微推量意图前瞻性记录并经DICOM确认,采用多变量分析评估与微推量接受的相关性,混合效应模型评估机构间变异。

主要发现

  • 多数患者接受EBRT未联合近距离治疗(71%,n=524/741)。
  • 接受EBRT的患者中,少数接受微推量(10%,n=53/524),分布于部分中心(27%,n=7/26),研究期间使用率无变化(P=.62)。
  • Grade分组4/5(OR=2.35;95%CI:1.02-5.28)、MRI计划(OR=6.34;95%CI:2.16-27.12)和基准标记/直肠间隔物放置(OR=2.59;95%CI:1.14-6.70)与微推量使用相关。
  • 存在显著的机构间变异(最低0%;95%CI:0.0-10.7至最高71%;95%CI:55.5-83.2,未校正,P<.0001)。
  • 中位推量体积为20.7cc,中位推量D98%为94.4 EQD2Gy;与非微推量病例相比,微推量队列直肠中位剂量增加(如V20Gy[EQD2] 53.8% vs 36.5%,P=.03),但超过NRG/RTOG膀胱/直肠约束的比例低且两组间无显著差异。

关键数值与推荐

  • 微推量使用与Grade分组4/5相关(OR=2.35;95%CI:1.02-5.28)。
  • 微推量使用与MRI计划相关(OR=6.34;95%CI:2.16-27.12)。
  • 微推量使用与基准标记/直肠间隔物放置相关(OR=2.59;95%CI:1.14-6.70)。
  • 机构间微推量使用率最低0%(95%CI:0.0-10.7),最高71%(95%CI:55.5-83.2),未校正P<.0001。
  • 微推量队列直肠V20Gy(EQD2)为53.8%,非微推量队列为36.5%(P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prospective trials have reported isotoxicity and improved oncologic outcomes with external beam radiation therapy (EBRT) microboost to a dominant intraprostatic lesion. There is often variability in the rate of adoption of new treatments, and current microboost practice patterns are unknown. We leveraged prospectively collected data from the multicenter Michigan Radiation Oncology Quality Consortium to understand the current state of microboost usage for localized prostate cancer. MATERIALS AND METHODS: Men with intermediate- and high-risk prostate adenocarcinoma treated with curative-intent radiation between October, 26, 2020, and June, 26, 2023, were included across 26 centers. Demographic-, tumor-, and treatment-related data along with DICOM files were prospectively collected. Microboost intent was prospectively documented and DICOM-confirmed. Multivariable analyses were used to evaluate associations with microboost receipt, and mixed-effects modeling evaluated facility-level variation. RESULTS: Most patients received EBRT without brachytherapy (71%, n = 524/741). Of those, a minority received an EBRT microboost (10%, n = 53/524) at a subset of sites (27%, n = 7/26), without a change in rate over the study period (P = .62). Grade group 4/5 (odds ration [OR] = 2.35; 95% confidence interval [CI]: 1.02-5.28), magnetic resonance imaging planning (OR = 6.34; 95%CI: 2.16-27.12), and fiducial marker/rectal spacer placement (OR = 2.59; 95% CI: 1.14-6.70) were associated with microboost use. Significant facility-level variability was present (minimum 0%; 95% CI: 0.0-10.7 to maximum 71%; 95% CI: 55.5-83.2, unadjusted, P < .0001). Median boost volume was 20.7cc, and median boost D98% was 94.4 EQD2Gy. Compared with non-microboost cases, intermediate doses to rectum in the microboost cohort were increased (eg, V20Gy [EQD2] of 53.8% vs 36.5%, P = .03). However, the proportion exceeding NRG/RTOG bladder/rectal constraints was low and not significantly different between cohorts. CONCLUSIONS: Despite prospective data demonstrating its benefit, EBRT microboost was used within a diverse statewide quality consortium in only 10% of cases at 27% of sites with significant facility-level heterogeneity. Concerted efforts are required to understand current barriers to microboost utilization, and results from trials such as PIVOTALboost (ISRCTN80146950) are eagerly awaited.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Regan SN, Dykstra M, Yin H, et al. Microboost in Localized Prostate Cancer: Analysis of a Statewide Quality Consortium. Adv Radiat Oncol. 2024. PMID: 39610797. doi:10.1016/j.adro.2024.101629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。